A Phase I study of MAX-40279 given orally to patients with acute myelogenous leukemia (AML)

Shortt, Jake (Primary Chief Investigator (PCI))

Medicine Monash Health

Project: Research

Project Description

NMA HREC Reference Number: HREC/18/SVH/97
NMA SSA Reference Number: SSA/18/MonH/489
Monash Health Ref: RES-18-0000-385X

Status	Finished
Effective start/end date	13/08/19 → 12/08/24

Keywords

clinical trial
phase 1 study
treatment efficacy
leukemia

Clinical Trial Phase

Phase I